Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy

Diabetes Care(2024)10.2337/dc23-1614Source: DataRank Database

Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy is a research paper published in Diabetes Care (2024). On theSindex it has a DataRank of 0. It has been cited 29 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access29 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 4.77)OA: bronzeTopics (60)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Salman Imam,Adam Neidert ORCID,ANABELA DILL GOMES ORCID,David T. Broome ORCID,Elif A Oral ORCID

Live enrichment

PubMed:38300898 PMC:PMC10973902 OpenAlex:https://openalex.org/W4391422602

NIH

Grant: R01DK125513

NIH

Grant: U54DK118612-04

NIDDK NIH HHS

Grant: U54 DK118612

National Institutes of Health

Grant: 5R01DK125513-03

Mechanisms of adipocyte loss in laminopathy-induced lipodystrophy in mice and humans

National Institutes of Health

Grant: 5U54DK118612-04

Center for Identification and Study of Individuals with Atypical Diabetes Mellitus

Caswell Diabetes Institute

FWCI

4.77

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

bronzeLicense: https://www.diabetesjournals.org/journals/pages/license

journalhttps://diabetesjournals.org/care/article-pdf/47/4/653/751769/dc231614.pdf

BRONZEhttps://diabetesjournals.org/care/article-pdf/47/4/653/751769/dc231614.pdf

publisherhttps://diabetesjournals.org/care/article-pdf/47/4/653/751769/dc231614.pdf

journalhttps://doi.org/10.2337/dc23-1614

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38300898

Fields of Study

Nuclear Structure and FunctionCaveolin-1 and cellular processesDiabetes Treatment and ManagementMedicine03 medical and health sciences0302 clinical medicineHumansFemaleMaleHypoglycemic AgentsRetrospective StudiesBlood GlucoseLipodystrophy, Familial PartialAcute DiseaseGlycated HemoglobinPancreatitisDiabetes Mellitus, Type 2Glucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

MeSH Terms

Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsAcute DiseaseBlood GlucoseDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansHypoglycemic AgentsMalePancreatitisRetrospective StudiesGlucagon-Like Peptide 1Lipodystrophy, Familial Partial

Keywords

MedicineLipodystrophyDiabetes mellitusGlucagon-like peptide-1Retrospective cohort studyGlucagonInternal medicineEndocrinologyInsulinHuman immunodeficiency virus (HIV)Type 2 diabetesImmunologyAntiretroviral therapyMaleBlood GlucoseGlycated HemoglobinBrief ReportLipodystrophy, Familial PartialPancreatitisDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Acute DiseaseHumansHypoglycemic AgentsFemaleRetrospective Studies

Sustainable Development Goals

SDG 0: Good health and well-being